Revolution Medicines, Inc. (RVMD)
| Market Cap | 40.08B +304.7% |
| Revenue (ttm) | n/a |
| Net Income | -1.77B |
| EPS | -8.92 |
| Shares Out | 214.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,720,154 |
| Open | 187.59 |
| Previous Close | 187.69 |
| Day's Range | 183.61 - 189.52 |
| 52-Week Range | 52.48 - 224.31 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 258.36 (+38.17%) |
| Earnings Date | Nov 4, 2026 |
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price target is $258.36, which is an increase of 38.17% from the latest price.
News
Revolution Medicines presents subgroup analyses from RASolute 302 trial
Revolution Medicines (RVMD) announced that exploratory subgroup analyses from the Phase 3 RASolute 302 trial were presented as a late-breaking abstract at the European Society for Medical Oncology, or...
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innov...
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innov...
Revolution Medicines begins treating patients in RASolve 308 trial
Revolution Medicines (RVMD) announced that it has begun treating patients in RASolve 308, a global Phase 3 clinical trial evaluating zoldonrasib, an investigational, RAS G12D-selective inhibitor, in c...
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
REDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innov...
Revolution Medicines price target raised to $241 from $240 at Truist
Truist raised the firm’s price target on Revolution Medicines (RVMD) to $241 from $240 and keeps a Buy rating on the shares ahead of its Q3 results. Investor feedback keeps…
Revolution Medicines initiated with an Outperform at William Blair
William Blair initiated coverage of Revolution Medicines (RVMD) with an Outperform rating. The firm believes the company will maintain its dominant position and move into earlier lines of therapy like...
Revolution Medicines receives positive CHMP opinion for RASONQUE
Revolution Medicines (RVMD) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion of RASONQUE once-daily oral tablets as a monoth...
EMA recommends approval of Revolution's pancreatic cancer drug
A European Medicines Agency committee on Thursday recommended approval of Revolution Medicines' Rasonque in the EU for adults with pancreatic cancer that has spread and worsened after at least on...
Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
Recommendation based on results from Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in risk of death compared with chemotherapy in the overall study population with statistically signi...
Revolution Medicines price target raised to $260 from $259 at RBC Capital
RBC Capital raised the firm’s price target on Revolution Medicines (RVMD) to $260 from $259 and keeps an Outperform rating on the shares after meeting with the company’s senior management.
Revolution Medicines price target lowered to $264 from $265 at BofA
BofA analyst Alex Stranahan lowered the firm’s price target on Revolution Medicines (RVMD) to $264 from $265 and keeps a Buy rating on the shares as part of a Q3…
RBC would be buyers of Revolution Medicines after FDA docs ‘overreaction’
RBC Capital notes Revolution Medicines (RVMD) looks to be down in response to yesterday’s disclosure of FDA’s Rasonque review documents, particularly the ORR data disclosed for the drug across RAS…
Revolution Medicines selloff ‘overdone and misguided,’ says TD Cowen
TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Revolution Medicines (RVMD), saying Thursday’s selloff on Rasonque’s reported efficacy in the G12D subpopulation looks “overdone and misguid...
Revolution selloff on FDA review docs should be bought, says Truist
Truist recommends using today’s selloff in shares of Revolution Medicines (RVMD) as a buying opportunity. The firm attributes the pullback to newly disclosed mutation-level efficacy data in the FDA re...
Revolution trading down after daraxonrasib review docs, says Stifel
Stifel says shares of Revolution Medicines (RVMD) are lower after the FDA posted multidisciplinary review documents for daraxonrasib with additional details on response by KRAS mutation. The FDA cauti...
Revolution Medicines price target raised to $259 from $251 at RBC Capital
RBC Capital raised the firm’s price target on Revolution Medicines (RVMD) to $259 from $251 and keeps an Outperform rating on the shares as part of a broader research note…
Propanc highlights preclinical data for PRP in pancreatic ductal adenocarcinoma
Propanc Biopharma (PPCB) highlighted new preclinical data for its candidate PRP in pancreatic ductal adenocarcinoma and compared that profile with a clinical standard recently established by Revolutio...
Revolution Medicines price target raised to $240 from $239 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Revolution Medicines (RVMD) to $240 from $239 and keeps a Buy rating on the shares as part of a broader…
Revolution Medicines begins treating patients in RASolute 309 trial
Revolution Medicines (RVMD) announced that it has begun treating patients in RASolute 309, a global, randomized Phase 3 clinical trial evaluating the combination of Rasonque, a RAS(ON) multi-selective...
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innov...
Revolution Medicines participates in a conference call with JPMorgan
JPMorgan holds a conference call with management on October 2 at 1 pm. Webcast Link
Revolution Medicines initiated with a Buy at Brookline
Brookline initiated coverage of Revolution Medicines (RVMD) with a Buy rating and $318 price target
Revolution Medicines resumed with a Buy at Goldman Sachs
Goldman Sachs resumed coverage of Revolution Medicines (RVMD) with a Buy rating and $267 price target Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform...
Revolution Medicines price target raised to $265 from $225 at BofA
BofA raised the firm’s price target on Revolution Medicines (RVMD) to $265 from $225 and keeps a Buy rating on the shares. Despite falling off all-time highs over the past…